119 related articles for article (PubMed ID: 20646838)
21. Expression of the Mr 67,000 laminin receptor is an adverse prognostic indicator in human thyroid cancer: an immunohistochemical study.
Basolo F; Pollina L; Pacini F; Fontanini G; Ménard S; Castronovo V; Bevilacqua G
Clin Cancer Res; 1996 Oct; 2(10):1777-80. PubMed ID: 9816129
[TBL] [Abstract][Full Text] [Related]
22. Intercellular adhesion molecule-1 (ICAM-1) immunoreactivity in well-differentiated thyroid papillary carcinomas.
Tanda F; Cossu A; Bosincu L; Manca A; Ibba M; Massarelli G
Mod Pathol; 1996 Jan; 9(1):53-6. PubMed ID: 8821957
[TBL] [Abstract][Full Text] [Related]
23. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.
Xu X; Quiros RM; Maxhimer JB; Jiang P; Marcinek R; Ain KB; Platt JL; Shen J; Gattuso P; Prinz RA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5968-79. PubMed ID: 14676122
[TBL] [Abstract][Full Text] [Related]
24. Flow cytometric DNA measurement in benign and malignant human thyroid tissues.
Mizukami Y; Nonomura A; Michigishi T; Kosaka T; Noguchi M; Nakamura S; Hashimoto T
Anticancer Res; 1992; 12(6B):2213-7. PubMed ID: 1295468
[TBL] [Abstract][Full Text] [Related]
25. [Expression of protein p53: the marker of low neoplastic cell differentiation in thyroid carcinoma].
Szybiński P; Nowak W; Stachura J; Nowak K; Przybylik-Mazurek E; Buziak-Bereza M
Wiad Lek; 2001; 54 Suppl 1():88-94. PubMed ID: 12182067
[TBL] [Abstract][Full Text] [Related]
26. Expression of cytokeratin 20 in thyroid carcinomas and peripheral blood detected by reverse transcription polymerase chain reaction.
Weber T; Lacroix J; Weitz J; Amnan K; Magener A; Hölting T; Klar E; Herfarth C; von Knebel Doeberitz M
Br J Cancer; 2000 Jan; 82(1):157-60. PubMed ID: 10638983
[TBL] [Abstract][Full Text] [Related]
27. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
28. uPA receptor expression in benign and malignant thyroid tumors.
Kim SJ; Shiba E; Taguchi T; Tsukamoto F; Miyoshi Y; Tanji Y; Takai S; Noguchi S
Anticancer Res; 2002; 22(1A):387-93. PubMed ID: 12017319
[TBL] [Abstract][Full Text] [Related]
29. Reciprocal immunohistochemical expression of sodium/iodide symporter and hexokinase I in primary thyroid tumors with synchronous cervical metastasis.
Jung YH; Hah JH; Sung MW; Kim KH; Cho SY; Jeon YK
Laryngoscope; 2009 Mar; 119(3):541-8. PubMed ID: 19235753
[TBL] [Abstract][Full Text] [Related]
30. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
31. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.
Kawabata W; Suzuki T; Moriya T; Fujimori K; Naganuma H; Inoue S; Kinouchi Y; Kameyama K; Takami H; Shimosegawa T; Sasano H
Mod Pathol; 2003 May; 16(5):437-44. PubMed ID: 12748250
[TBL] [Abstract][Full Text] [Related]
33. Analysis of P161NK4A protein expression in follicular thyroid tumors.
Ferenc T; Lewiński A; Lange D; Niewiadomska H; Sygut J; Sporny S; Jarzab B; Sałacińska-Loś E; Kulig A; Włoch J
Pol J Pathol; 2004; 55(4):143-8. PubMed ID: 15757201
[TBL] [Abstract][Full Text] [Related]
34. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas.
Castellone MD; Guarino V; De Falco V; Carlomagno F; Basolo F; Faviana P; Kruhoffer M; Orntoft T; Russell JP; Rothstein JL; Fusco A; Santoro M; Melillo RM
Oncogene; 2004 Aug; 23(35):5958-67. PubMed ID: 15184868
[TBL] [Abstract][Full Text] [Related]
35. Cytokeratin expression profiles in thyroid carcinomas.
Lam KY; Lui MC; Lo CY
Eur J Surg Oncol; 2001 Nov; 27(7):631-5. PubMed ID: 11669590
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
37. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
38. The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions.
Davidson B; Dong HP; Holth A; Berner A; Risberg B
Breast J; 2008; 14(5):476-82. PubMed ID: 18657145
[TBL] [Abstract][Full Text] [Related]
39. [Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland].
Kazantseva IA; Fedosenko AK; Gurevich LE
Arkh Patol; 2001; 63(4):18-21. PubMed ID: 11534185
[TBL] [Abstract][Full Text] [Related]
40. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology.
McCaffrey JC
Laryngoscope; 2006 Jan; 116(1):1-11. PubMed ID: 16481800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
